IPQ Inside the global regulatory dialogue

Stronger Unapproved Stem-Cell Enforcement Accompanies FDA Center for Biologics’ Cell and Gene Therapy Advancement Efforts

Sep 14th, 2020

Please Log in to print the full article

PART I Comparing the Stem-Cell and Gene Therapy Landscapes CBER Director Peter Marks is strongly affirming the center’s commitment to support the development of safe and effective stem-cell therapies in discussing the enforcement actions it...

You must be a paid subscriber to continue reading this article. If you are a paid subscriber, please Log in. If you are not a paid subscriber, please subscribe now.

©2020 IPQ Publications